Under the agreed upon terms Sigma-Aldrich gained access to the QuantiGene gene expression profiling assay and Genospectra’s technologies for inducible siRNA, a unique nano-particle system for delivery of siRNA and other biomolecules to cells.
The companies will participate in a joint program to develop new technology and products in the area of cell-based assays.
“Sigma-Aldrich’s leadership and capabilities in technology commercialization and product development, combined with Genospectra’s cutting edge platforms in the area of systems biology, provides significant potential for success,” said Dr David Smoller, vice president of R&D for Sigma-Aldrich’s research biotech business unit.